Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child-Pugh A category: A multicenter study.

Ying ZhangKazushi NumataKento ImajoHaruki UojimaAkihiro FunaokaSatoshi KomiyamaKatsuaki OgushiMakoto ChumaKuniyasu IrieShigehiro KokubuMasato YonedaTakashi KobayashiHisashi HidakaTaito FukushimaSatoshi KobayashiManabu MorimotoTatehiro KagawaNobuhiro HattoriTsunamasa WatanabeShigeru IwaseShin Maeda

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2024)

Lenvatinib RFA sequential therapy might offer favorable tolerability and potential prognostic improvement compared to lenvatinib monotherapy.

Keyphrases

radiofrequency ablation
open label
mental health
randomized controlled trial
clinical trial
risk assessment
bone marrow
climate change
double blind